Reuters logo
BRIEF-Acorda announces 2016 AMPYRA net sales and 2017 financial guidance
January 9, 2017 / 11:19 AM / 10 months ago

BRIEF-Acorda announces 2016 AMPYRA net sales and 2017 financial guidance

Jan 9 (Reuters) - Acorda Therapeutics Inc :

* Acorda announces 2016 AMPYRA net sales and 2017 financial guidance at J.P. Morgan healthcare conference

* Sees FY 2017 sales $535 million to $545 million

* Q4 sales $132 million versus I/B/E/S view $137.5 million

* Acorda Therapeutics - continue to enroll Phase 3 study of tozadenant in people with parkinson’s and expect topline data from study in Q1 of 2018

* Acorda Therapeutics Inc - at year-end 2016, company projects cash, cash equivalents and investments of approximately $155 million (unaudited)

* Acorda Therapeutics - on track to announce topline data from CVT-301 phase 3 efficacy,long-term safety trials for treatment of off periods in parkinson’s Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below